Press Releases - 2022-08-11

Date	Title	Company
11-Aug-2022	Nouscom announces leading publication revealing an immune mechanism of action driving anti-tumor activity of adenovirus vectored vaccines and anti-PD1 immunotherapy	Nouscom
11-Aug-2022	Aqilion starts Phase 1 clinical trial with drug candidate AQ280 for chronic inflammatory diseases	AQILION AB
11-Aug-2022	iTeos Reports Second Quarter 2022 Financial Results and Provides Business Update	iTeos
11-Aug-2022	Genmab Announces Financial Results for the First Half of 2022	Genmab
11-Aug-2022	Ear Health Market is CAGR of 6.3% during the forecast period 2022-2032	MARKITWIRED
11-Aug-2022	Drug Screening Market is a CAGR of 16% during the forecast period 2022-2032	MARKITWIRED
11-Aug-2022	Surgical Instruments Tracking System Market is projected to grow at a rate of 15% CAGR during the forecast period 2022-2032	MARKITWIRED
11-Aug-2022	Self Testing Market is projected to record a CAGR of 5.5% amid the forecast period by 2030	MARKITWIRED
11-Aug-2022	Orthopaedic Prosthetics Market will witness a CAGR of over 4.5% during forecast period by 2030	MARKITWIRED
11-Aug-2022	Over-the-Counter Pain Medication Market is predicted to rise at a CAGR of 4.1% from 2022 to 2028	MARKITWIRED
11-Aug-2022	Black & Veatch Completes World’s First Commercial-Scale Alternative Animal Feed Production Facility	Businesswire
11-Aug-2022	Companion Animals Drug Market is projected to increase from a valuation of US$ 36.94 Billion in 2022	MARKITWIRED
11-Aug-2022	Eckert & Ziegler with Successful First Half of 2022	Eckert & Ziegler Strahlen- und Medizintechnik AG
11-Aug-2022	Medios AG continues record course: Strong growth in the first half of 2022	Medios AG
11-Aug-2022	APONTIS PHARMA expands profitable positioning in first half of 2022 – full-year forecast confirmed	APONTIS PHARMA AG
11-Aug-2022	Evotec SE reports results for the first half-year 2022 and provides corporate updates	Evotec SE
11-Aug-2022	SYNLAB reports solid H1 2022 results and raises 2022 revenue guidance	SYNLAB AG
11-Aug-2022	Biotest AG: Biotest achieves an improved adjusted EBIT by 9.8% of EUR 32.4 million in the first half of 2022	Biotest AG